{"id":"NCT01359449","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations","officialTitle":"Safety and Immunogenicity of Two Doses of Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2012-07","completion":"2012-11","firstPosted":"2011-05-24","resultsPosted":"2013-05-24","lastUpdate":"2016-08-19"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Meningococcal Group C Conjugate vaccine: MenC","otherNames":["Menjugate","MenC"]}],"arms":[{"label":"Menactra® Vaccine Group","type":"EXPERIMENTAL"},{"label":"Menjugate® Vaccine Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose for this study is to demonstrate the safety and immunogenicity of two doses of Menactra® administered between 12 and 18 months of age and concomitantly with routine immunization with two different provincial schedule\n\nPrimary Objectives:\n\n* To describe the immunogenicity of Menactra® administered concomitantly with routine immunizations at 12 and 18 months in naïve or Menjugate-primed (MenC-primed) infants (measured by serum bactericidal assay using baby rabbit complement \\[SBA-BR\\])\n* To describe the immunogenicity of MenC administered concomitantly with routine immunizations at 12 months of age (measured by SBA-BR)\n\nSecondary Objectives:\n\nSafety\n\n* To describe the safety profile of Menactra® and MenC vaccines after each dose when given concomitantly with routine immunization.\n\nImmunogenicity\n\n* To describe the immunogenicity of both vaccines using serum bactericidal assay using human complement \\[SBA-HC\\]\n* To describe the immunogenicity of Pediacel administered at 18 months.","primaryOutcome":{"measure":"Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.","timeFrame":"28 days post-vaccination","effectByArm":[{"arm":"Menactra® Vaccine Group","deltaMin":null,"sd":null},{"arm":"Menjugate® Vaccine Group","deltaMin":4.34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":["25285126"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":61},"commonTop":["Irritability","Anorexia","Injection site Tenderness","Injection site Erythema","Crying"]}}